ViroLogic Launches VLink Online System for HIV Resistance Test Reporting
March 30 2004 - 6:30AM
PR Newswire (US)
ViroLogic Launches VLink Online System for HIV Resistance Test
Reporting Internet Access to Test Results Adds Convenience and
Reduces Turnaround Time SOUTH SAN FRANCISCO, Calif., March 30
/PRNewswire-FirstCall/ -- ViroLogic, Inc. today announced the
launch of VLink online test reporting for its comprehensive
portfolio of HIV drug resistance assays, PhenoSense GT(TM),
PhenoSense(TM) HIV and GeneSeq(TM) HIV. The VLink system is
designed to offer a fast and convenient way for healthcare
professionals to access test results via a secure Internet
connection. "Creating secure and convenient online access to
up-to-date test results will help improve patient care," said
Stephen Becker, MD, Associate Clinical Professor of Medicine at the
University ofCalifornia, San Francisco and an HIV specialist in
private practice. "ViroLogic's online reporting system is a useful
tool that places current and historical testing information at my
fingertips and provides efficiencies that are not realized by
paper-based systems." Increasingly, healthcare organizations are
improving efficiency through the adoption of electronic or
web-based procedures. ViroLogic's secure new online system
facilitates data analysis, allowing examination of historical
patient resistance data to help identify resistance patterns in
patients over time. Importantly, this service is expected to
shorten the time period between sample submission and reporting of
results. The Company believes the system is fully compliant with
the patient confidentiality regulations outlined in the Health
Insurance Portability and Accountability Act (HIPAA). "VLink is
intended to facilitate rapid HIPAA-compliant access to test
results, enabling more prompt and informed management of patients
withHIV," said Tien Bui, ViroLogic's Vice President of Sales and
Marketing. "We are committed to building on our leadership position
in HIV resistance testing through continued enhancement of our
products and services to healthcare providers." Interestedcustomers
may register for this service by contacting ViroLogic's Customer
Service department at 800-777-0177 or by e-mail at . The online
reporting service is also available to ViroLogic's pharmaceutical
and clinical research collaborators. About ViroLogic ViroLogic is a
biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide
and improve treatment of serious viral diseases such as AIDS and
hepatitis. The Company's products aredesigned to help doctors
optimize treatment regimens for their patients that lead to better
outcomes and reduced costs. The Company's technology is also being
used by numerous biopharmaceutical companies to develop new and
improved antiviral therapeutics and vaccines targeted at emerging
drug-resistant viruses. More information about the Company and its
technology can be found on its web site at
http://www.virologic.com/. Certain statements in this press release
are forward-looking, including statements relating to overall
turnaround time, efficiencies resulting from electronic reporting,
and compliance with HIPAA. These forward-looking statements are
subject to risks and uncertainties and other factors, which may
cause actual results to differmaterially from the anticipated
results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks that the Company's products may not perform
in the same manner as indicated in this press release, whether
ViroLogic successfully introduces new products, whether others
introduce competitive products, the risk that the Company's
products for patient testing may not continue to be accepted or
that increased demand from drug development partners may not
develop as anticipated, the risk that gross margins may not
increase as expected, the risk that ViroLogic may not continue to
realize anticipated benefits from its cost-cutting measures, the
timing of pharmaceutical company clinical trials, whether payors
will authorize reimbursement for its products, whether the FDA or
any other agency will decide to regulate ViroLogic's products or
services, whether the Company will encounter problems or delays in
automating its processes, whether ViroLogic successfully introduces
new products, whether others introduce competitive products,
whether intellectual property underlying the Company's PhenoSense
technology is adequate, whether licenses to third party technology
will be available, whether ViroLogic is able to build brand loyalty
and expand revenues, and whether ViroLogic will be able to raise
sufficient capital when required. For a discussion of other factors
that may cause ViroLogic's actual events to differ from those
projected, please refer to the Company's most recent annual report
on Form 10-K and quarterly reports on Form 10-Q, as well as other
subsequent filings with the Securities and Exchange Commission.
DATASOURCE: ViroLogic, Inc. CONTACT: Karen Wilson,CFO of ViroLogic,
+1-650-624-4164, or Web site: http://www.virologic.com/
Copyright
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Virologic (MM) (NASDAQ): 0 recent articles
More Virologic (MM) News Articles